A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.
A top three of early-stage CAR-T presentations from this year’s Ash meeting that you might have missed.
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.